Variable | All cases | Serum CRP mg/L | P valuea | |
---|---|---|---|---|
≤1.8 | > 1.8 | |||
Age (years) | Â | Â | Â | 0.355 |
  ≤ 55b | 75 | 21 (28.0 %) | 54 (72.0 %) |  |
  > 55 | 71 | 21 (32.3 %) | 44 (67.7 %) |  |
Gender | Â | Â | Â | 0.018 |
 Male | 93 | 22 (23.7 %) | 71 (76.3 %) |  |
 Female | 47 | 20 (42.6 %) | 27 (57.4 %) |  |
Location | Â | Â | Â | 0.263 |
 Right lobe | 75 | 26 (34.7 %) | 49 (65.3 %) |  |
 Left lobe | 46 | 13 (28.3 %) | 33 (71.7 %) |  |
Both lobes or quadrate lobe | 19 | 3 (15.8Â %) | 16 (84.2Â %) | Â |
 ALT |  |  |  | < 0.001 |
 Normal | 87 | 37 (42.5 %) | 50 (57.5 %) |  |
 Elevated | 53 | 5 (9.4 %) | 48 (90.6 %) |  |
AST | Â | Â | Â | 0.002 |
 Normal | 97 | 37 (38.1 %) | 60 (61.9 %) |  |
 Elevated | 43 | 5 (11.6 %) | 38 (88.4 %) |  |
HbsAg | Â | Â | Â | 0.417 |
 Positive | 55 | 15 (27.3 %) | 40 (72.7 %) |  |
 Negative | 82 | 25 (30.5 %) | 57 (69.5 %) |  |
CEA (ng/ml) | Â | Â | Â | 0.047 |
  ≤ 5 | 101 | 35 (34.7 %) | 66 (65.3 %) |  |
  > 5 | 38 | 7 (16.7 %) | 31 (81.6 %) |  |
CA19-9 (U/ml) | Â | Â | Â | 0.024 |
  ≤ 35 | 57 | 23 (40.4 %) | 34 (59.6 %) |  |
  > 35 | 82 | 19 (23.2 %) | 63 (76.8 %) |  |
Tumor size (cm) | Â | Â | Â | 0.119 |
  ≤ 5.5c | 71 | 25 (35.2 %) | 46 (64.8 %) |  |
  > 5.5 | 69 | 17 (24.6 %) | 52 (75.4 %) |  |
Nodal metastasis | Â | Â | Â | 0.158 |
 Yes | 29 | 6 (20.7 %) | 23 (79.3 %) |  |
 No | 111 | 36 (32.4 %) | 75 (67.6 %) |  |
Tumor multiplicity | Â | Â | Â | 0.830 |
 Single | 108 | 32 (29.6 %) | 76 (70.4 %) |  |
 Multiple | 32 | 10 (31.2 %) | 22 (68.8 %) |  |
Intraepithelial ductal spread | Â | Â | Â | 0.039 |
 Absent | 52 | 21 (40.4 %) | 31 (59.6 %) |  |
 Present | 88 | 21 (23.9 %) | 67 (76.1 %) |  |
Vascular invasion | Â | Â | Â | 0.940 |
 Absent | 86 | 26 (30.2 %) | 60 (69.8 %) |  |
 Present | 54 | 16 (29.6 %) | 38 (70.4 %) |  |
Grade | Â | Â | Â | 0.185 |
 I | 14 | 7 (50.0 %) | 7 (50.0 %) |  |
 II | 77 | 23 (29.9 %) | 31 (70.1 %) |  |
 III | 49 | 12 (24.5 %) | 37 (75.5 %) |  |
TNM | Â | Â | Â | 0.011 |
 I-II | 78 | 30 (38.5 %) | 48 (61.5 %) |  |
 III- IV | 62 | 12 (19.4 %) | 50 (80.6 %) |  |
Postoperative chemotherapy | Â | Â | Â | 0.078 |
 Yes | 47 | 10 (21.3 %) | 37 (78.7 %) |  |
 No | 93 | 32 (34.4 %) | 61 (65.6 %) |  |